Navigation Links
Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
Date:9/13/2012

RIDGEFIELD, Conn., Sept. 13, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access program (EAP) for its investigational, oncology compound, afatinib.1  The EAP will be available to eligible patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an epidermal growth factor receptor (EGFR) mutation.1  Healthcare professionals and patients can learn more about the afatinib EAP by calling +1 855-EAP-BIPI (855-327-2474) or by visiting clinicaltrials.gov.  Afatinib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA). 

Under certain circumstances, the FDA allows companies in the late stages of drug development to offer early access programs of investigational compounds, such as afatinib.  These programs are specifically for those patients who are not eligible to enroll in a clinical trial and who have serious or immediately life-threatening illnesses for which there are no comparable or satisfactory alternate therapies.2 

"Patients with EGFR mutation-positive advanced NSCLC currently have limited treatment options," said Berthold Greifenberg, MD, vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "Boehringer Ingelheim has chosen to initiate this EAP because of its commitment to these patients.  This program will provide eligible patients with early access to afatinib and we are currently working rapidly to prepare and submit a new drug application to the FDA."

About the Afatinib EAP 

The afatinib EAP (clinical trial identifier NCT01649284) is an open-label, multi-center trial for patients with locally advanced
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
2. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
3. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
7. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
8. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
9. Henry Schein Announces New $500 Million Credit Facility
10. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
11. Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Oct. 15 /PRNewswire-FirstCall/,-- Lexicon Pharmaceuticals, Inc. (Nasdaq: ... clinical trial results for LX1031 at the ... in Philadelphia, Pennsylvania. The,studies demonstrated that LX1031 ... that exposure levels in blood were low. ...
... control in patients with type ... has been accepted for publication, OWINGS MILLS, Md., Oct. ... a study conducted by researchers at the,Johns Hopkins University Bloomberg ... peer-reviewed journal which is scheduled for,release in an early 2008 ...
Cached Medicine Technology:Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 2Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 3Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study 2
(Date:1/23/2015)... 2015 Hastings and Hastings, a law firm ... record number of legal representation client review requests for slip ... a steady rise in the number of slip and fall ... throughout the Valley. With that said, a large number of ... an experienced law firm. Hastings and Hastings is a personal ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... , FRIDAY, Feb. 25 (HealthDay News) -- Infants ... for childhood obesity, but breast-feeding lowers that risk, a new ... those who were breast-fed for six months or more were ... were 6 to 13 years old than children whose mothers ...
... , FRIDAY, Feb. 25 (HealthDay News) -- Depression ... and 40s who are prone to addiction problems and ... at how personal history, family life and neighborhood instability ... period during their early years of marriage and motherhood. ...
... FRIDAY, Feb. 25 (HealthDay News) -- Most patients struggling ... called idiopathic pulmonary fibrosis do not risk ... exposure to a viral infection, new research indicates. ... viral infections might rapidly advance disease in patients diagnosed ...
... Reporter , THURSDAY, Feb. 24 (HealthDay News) -- Experts ... of impending dangers to human health if greenhouse gas ... the federal government, specifically the Environmental Protection Agency, ... "The science is unequivocal that global warming is ...
... drug that is currently used to help treat bone metastases ... an earlier stage of treatment, to prevent the cancer from ... Dr Michela Quirino and colleagues from the Catholic University of ... that zoledronic acid may be able to prevent lung cancer ...
... THURSDAY, Feb. 24 (HealthDay News) -- While experts stress that ... past, isolated cases still appear, even in the United States. ... American lab worker died from plague in 2009 -- the ... and the first known death from a weakened form of ...
Cached Medicine News:Health News:Breast-Feeding May Cut Obesity Risk in Kids of Diabetic Moms 2Health News:Depression May Worsen Over Time in Addiction-Prone Women 2Health News:Virus Unlikely to Advance Deadly Lung Disease: Study 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:Bone drug zoledronic acid may help prevent spread of early lung cancer 2Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3